Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Colon and Rectum

Bartley, Angela N.; Hamilton, Stanley R.; Alsabeh, Randa; Ambinder, Edward P.; Berman, Michael A.; Collins, Emma; Fitzgibbons, Patrick L.; Gress, Donna M.; Nowak, Jan A.; Samowitz, Wade S.; Zafar, S. Yousuf

doi:10.5858/arpa.2013-0231-cp

Cited by 52 publications

(38 citation statements)

References 19 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is despite the inclusion of microsatellite instability, and staining for mismatch repair proteins, KRAS, BRAF and PTEN in the template for reporting results of biomarker testing in CRC by the College of American Pathologists [41]. The proportion of cases with high-grade tumour budding ranges from 6 to 51 % in the more relevant published literature [42], and in the studies included in this meta-analysis (with the exception of the study by Park et al in which budding was described as either present or absent), this proportion ranged from 18 to 57 %.…”

Section: Discussionmentioning

confidence: 92%

Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis

Petrelli

Pezzica

Cabiddu

et al. 2015

J Gastrointest Canc

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 92%

Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis

Petrelli

Pezzica

Cabiddu

et al. 2015

J Gastrointest Canc

View full text Add to dashboard Cite

show abstract

“…KRAS results are part of the College of American Pathologists (CAP) protocol, but reporting is optional; partly because this result is not always available when the pathology report is issued. 30 Thus, KRAS testing may not always be documented in the pathology report, or it may be added as an addendum at a later time, potentially after the report was abstracted by the cancer registrar. In addition, physician offices, or even hospitals, may send specimens to private out-of-state pathology laboratories for KRAS testing, and some of these laboratories may not be a case finding source for the registries.…”

Section: Discussionmentioning

confidence: 99%

Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients

Charlton

Karlitz

Schlichting

et al. 2017

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Objectives Response to epidermal growth factor receptor inhibitors is poorer among Stage IV colorectal cancer (CRC) patients with KRAS mutations, thus KRAS testing is recommended prior to treatment. KRAS testing was collected by Surveillance, Epidemiology, and End Results (SEER) registries for 2010 CRC cases, and our goal was to provide the first population-based estimates of testing in the U.S. Methods SEER CRC cases diagnosed in 2010 were evaluated (n=30,351). Chi-square tests and logistic regression were conducted to determine patient characteristics associated with KRAS testing, stratified by Stages I-III vs. Stage IV. Log-rank tests were used to examine survival by testing status. Results KRAS testing among Stage IV cases ranged from 39% in New Mexico to 15% in Louisiana. In the model, younger age, being married, living in a metropolitan area, and having primary site surgery were associated with greater odds of receiving KRAS testing. Those who received testing had significantly better survival then those who did not (p<0.0001). Among those who received testing, there was no significant difference in survival by mutated vs. wild type KRAS. Five percent of Stage I-III cases received testing. Conclusions Wide variation in documented KRAS testing for Stage IV CRC patients exists among SEER registries. Age remained highly significant in multivariate models, suggesting it plays an independent role in the patient and/or provider decision to be tested. Further research is needed to determine drivers of variation in testing, as well as reasons for testing in Stage I-III cases where it is not recommended.

show abstract

“…The latest diagnostic guidelines for CRC from the College of American Pathologists (CAP) and the American Joint Committee on Cancer (AJCC), published in 2013, include the following [15]:…”

Section: Laboratory Accreditationmentioning

confidence: 99%

Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

et al. 2014

View full text Add to dashboard Cite

Publication of this consensus statement is a joint initiative of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM), intended to revise and update the diagnostic and treatment recommendations published 2 years ago on biomarker use and the management of patients with colorectal carcinoma (CRC), thereby providing an opportunity to improve healthcare efficiency and resource use in these patients. This expert group recommends testing for KRAS and NRAS status in all patients with metastatic CRC being considered for anti-epidermal growth factor receptor (anti-EGFR) therapy, as this type of treatment should only be used in patients not harbouring mutations in these genes. In contrast, testing for BRAF, EGFR, PI3K and PTEN mutation status is not necessary for therapeutic decision making, so does not need to be done routinely.

show abstract

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Colon and Rectum

Cited by 52 publications

References 19 publications

Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis

Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis

Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients

Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Contact Info

Product

Resources

About